Concepts (98)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mouth Neoplasms | 4 | 2024 | 63 | 2.680 |
Why?
|
| Areca | 4 | 2022 | 4 | 2.310 |
Why?
|
| Measles | 3 | 2025 | 5 | 1.000 |
Why?
|
| Carcinoma, Verrucous | 1 | 2024 | 1 | 0.930 |
Why?
|
| Parasites | 2 | 2022 | 11 | 0.910 |
Why?
|
| Communicable Diseases | 1 | 2024 | 21 | 0.880 |
Why?
|
| Nuts | 1 | 2022 | 2 | 0.800 |
Why?
|
| Toxoplasma | 1 | 2022 | 32 | 0.740 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2020 | 6 | 0.680 |
Why?
|
| Radiotherapy | 1 | 2020 | 41 | 0.670 |
Why?
|
| Substance-Related Disorders | 1 | 2022 | 185 | 0.650 |
Why?
|
| Carcinoma | 1 | 2020 | 75 | 0.640 |
Why?
|
| Nasal Septum | 1 | 2019 | 3 | 0.630 |
Why?
|
| Rhinoplasty | 1 | 2019 | 4 | 0.620 |
Why?
|
| Nasal Obstruction | 1 | 2019 | 7 | 0.620 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 296 | 0.540 |
Why?
|
| Micronesia | 3 | 2020 | 5 | 0.500 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 678 | 0.450 |
Why?
|
| Measles Vaccine | 3 | 2025 | 4 | 0.430 |
Why?
|
| Lymphatic Metastasis | 2 | 2024 | 125 | 0.390 |
Why?
|
| Humans | 13 | 2025 | 28121 | 0.380 |
Why?
|
| Mastication | 2 | 2022 | 4 | 0.370 |
Why?
|
| Neoplasm Staging | 2 | 2024 | 478 | 0.360 |
Why?
|
| Measles virus | 2 | 2022 | 3 | 0.340 |
Why?
|
| Vaccination | 3 | 2025 | 183 | 0.310 |
Why?
|
| Immunization Schedule | 2 | 2025 | 11 | 0.300 |
Why?
|
| Young Adult | 3 | 2020 | 2731 | 0.290 |
Why?
|
| Protozoan Proteins | 2 | 2024 | 52 | 0.250 |
Why?
|
| Risk Factors | 2 | 2022 | 2084 | 0.250 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 969 | 0.250 |
Why?
|
| Immunization Programs | 1 | 2025 | 14 | 0.240 |
Why?
|
| Advisory Committees | 1 | 2025 | 32 | 0.240 |
Why?
|
| Vaccines | 1 | 2025 | 33 | 0.230 |
Why?
|
| Immunization | 1 | 2025 | 120 | 0.230 |
Why?
|
| Biosurveillance | 1 | 2024 | 1 | 0.230 |
Why?
|
| Seroepidemiologic Studies | 1 | 2024 | 10 | 0.230 |
Why?
|
| Apicomplexa | 1 | 2024 | 4 | 0.220 |
Why?
|
| Middle Aged | 3 | 2020 | 7164 | 0.220 |
Why?
|
| Adult | 3 | 2020 | 7757 | 0.210 |
Why?
|
| Protein Kinases | 1 | 2024 | 158 | 0.200 |
Why?
|
| Proteomics | 1 | 2024 | 181 | 0.200 |
Why?
|
| Nucleotides, Cyclic | 1 | 2022 | 4 | 0.190 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2022 | 16 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 330 | 0.190 |
Why?
|
| Malaria Vaccines | 2 | 2025 | 2 | 0.190 |
Why?
|
| Cyclic GMP | 1 | 2022 | 29 | 0.190 |
Why?
|
| Cyclic AMP | 1 | 2022 | 86 | 0.190 |
Why?
|
| Zinc Oxide | 1 | 2021 | 3 | 0.180 |
Why?
|
| Female | 5 | 2020 | 15156 | 0.180 |
Why?
|
| Male | 4 | 2020 | 13487 | 0.180 |
Why?
|
| Staphylococcus aureus | 1 | 2021 | 117 | 0.170 |
Why?
|
| Mouth Mucosa | 1 | 2020 | 16 | 0.170 |
Why?
|
| Medically Uninsured | 1 | 2020 | 32 | 0.170 |
Why?
|
| Lymph Nodes | 1 | 2020 | 103 | 0.160 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 238 | 0.160 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 226 | 0.160 |
Why?
|
| Binge Drinking | 1 | 2019 | 8 | 0.160 |
Why?
|
| Survival Rate | 1 | 2020 | 430 | 0.160 |
Why?
|
| Asymptomatic Infections | 1 | 2019 | 1 | 0.160 |
Why?
|
| Disease Reservoirs | 1 | 2019 | 6 | 0.160 |
Why?
|
| Constriction, Pathologic | 1 | 2019 | 34 | 0.150 |
Why?
|
| Malaria, Falciparum | 1 | 2019 | 6 | 0.150 |
Why?
|
| Tobacco Use | 1 | 2020 | 99 | 0.150 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 14 | 0.150 |
Why?
|
| Saliva | 1 | 2019 | 96 | 0.150 |
Why?
|
| Health Behavior | 1 | 2019 | 156 | 0.140 |
Why?
|
| Cigarette Smoking | 1 | 2019 | 81 | 0.140 |
Why?
|
| Prevalence | 1 | 2019 | 494 | 0.140 |
Why?
|
| Disease Eradication | 1 | 2017 | 9 | 0.140 |
Why?
|
| Global Health | 1 | 2017 | 51 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 523 | 0.130 |
Why?
|
| Malaria | 1 | 2016 | 17 | 0.130 |
Why?
|
| World Health Organization | 2 | 2025 | 12 | 0.120 |
Why?
|
| Adolescent | 2 | 2020 | 3123 | 0.120 |
Why?
|
| Animals | 3 | 2024 | 10399 | 0.110 |
Why?
|
| Retrospective Studies | 1 | 2020 | 2557 | 0.110 |
Why?
|
| Aged | 1 | 2019 | 5416 | 0.080 |
Why?
|
| Infant | 2 | 2025 | 996 | 0.070 |
Why?
|
| Typhoid-Paratyphoid Vaccines | 1 | 2025 | 1 | 0.060 |
Why?
|
| Vaccination Coverage | 1 | 2025 | 13 | 0.060 |
Why?
|
| Influenza Vaccines | 1 | 2025 | 51 | 0.060 |
Why?
|
| Substrate Specificity | 1 | 2024 | 151 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2024 | 102 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2024 | 575 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 79 | 0.050 |
Why?
|
| Optogenetics | 1 | 2021 | 8 | 0.050 |
Why?
|
| Crystallization | 1 | 2021 | 50 | 0.050 |
Why?
|
| Surface Properties | 1 | 2021 | 134 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2021 | 148 | 0.040 |
Why?
|
| Parasitemia | 1 | 2019 | 1 | 0.040 |
Why?
|
| Zambia | 1 | 2019 | 3 | 0.040 |
Why?
|
| Cameroon | 1 | 2019 | 2 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2019 | 25 | 0.040 |
Why?
|
| Africa | 1 | 2016 | 16 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 755 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 968 | 0.030 |
Why?
|
| Sex Factors | 1 | 2016 | 465 | 0.030 |
Why?
|
| Child | 1 | 2019 | 2242 | 0.020 |
Why?
|